Linker Information
General Information of This Linker
| Linker ID |
LIN0CUHFM
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
US20250000991A1 Ab1 ADC Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C19H28N4O7
|
|||||
| Isosmiles |
C[C@H](NC([C@@H](NC(CCCCCN1C(C=CC1=O)=O)=O)C)=O)C(N[C@@H](C)C(O)=O)=O
|
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C19H28N4O7/c1-11(17(27)21-12(2)18(28)22-13(3)19(29)30)20-14(24)7-5-4-6-10-23-15(25)8-9-16(23)26/h8-9,11-13H,4-7,10H2,1-3H3,(H,20,24)(H,21,27)(H,22,28)(H,29,30)/t11-,12-,13-/m0/s1
|
|||||
| InChIKey |
UCOOONSXCROXON-AVGNSLFASA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
424.454
|
Polar area
|
161.98
|
||
|
Complexity
|
677.5499552
|
xlogp Value
|
-0.9295
|
|||
|
Heavy Count
|
30
|
Rot Bonds
|
12
|
|||
|
Hbond acc
|
6
|
Hbond Donor
|
4
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
US20250000991A1 Ab1a ADC [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.0587 nM
|
High Nectin-4 expression (Nectin-4 +++) | ||
| Method Description |
Ab6 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
|
||||
| In Vitro Model | Bladder carcinoma | T24 mScarlet clone 5 nectin-4 negative cells | CVCL_0554 | ||
US20250000991A1 Ab3 ADC [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.0694 nM
|
High Nectin-4 expression (Nectin-4 +++) | ||
| Method Description |
Ab8 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
|
||||
| In Vitro Model | Bladder carcinoma | T24 mScarlet clone 5 nectin-4 negative cells | CVCL_0554 | ||
US20250000991A1 Ab1 ADC [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.0766 nM
|
High Nectin-4 expression (Nectin-4 +++) | ||
| Method Description |
Ab5 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
|
||||
| In Vitro Model | Bladder carcinoma | T24 mScarlet clone 5 nectin-4 negative cells | CVCL_0554 | ||
US20250000991A1 Ab2 ADC [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.0836 nM
|
High Nectin-4 expression (Nectin-4 +++) | ||
| Method Description |
Ab7 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
|
||||
| In Vitro Model | Bladder carcinoma | T24 mScarlet clone 5 nectin-4 negative cells | CVCL_0554 | ||